CINECA IRIS Institutional Research Information System

SINICCO, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.317
EU - Europa 861
AS - Asia 507
AF - Africa 4
SA - Sud America 1
Totale 2.690
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.293
CN - Cina 309
UA - Ucraina 122
IE - Irlanda 120
SG - Singapore 107
DE - Germania 96
FR - Francia 95
IT - Italia 93
SE - Svezia 92
FI - Finlandia 78
KR - Corea 73
DK - Danimarca 51
GB - Regno Unito 48
AT - Austria 36
CA - Canada 24
PL - Polonia 16
VN - Vietnam 11
BE - Belgio 10
IN - India 6
NL - Olanda 3
MU - Mauritius 2
SN - Senegal 2
PE - Perù 1
PH - Filippine 1
RU - Federazione Russa 1
Totale 2.690
Salva come PNG Salva come JPEG
Città #
Beijing 265
Santa Clara 181
Ann Arbor 164
Chandler 154
Dublin 120
Singapore 95
Jacksonville 70
Villeurbanne 68
Houston 45
Princeton 44
Medford 43
Dearborn 41
Ashburn 39
Vienna 36
Columbus 30
Milan 24
Boston 19
Toronto 18
Nyköping 16
Warsaw 16
Wilmington 15
Boardman 13
Brussels 10
Verona 9
Woodbridge 9
Falls Church 7
Kunming 7
Lachine 6
New York 6
Norwalk 6
Torino 6
Guangzhou 5
Bisignano 4
Dong Ket 4
Jinan 4
Mountain View 4
Nanjing 4
Fremont 3
Kharkiv 3
Munich 3
Portici 3
Pune 3
Redmond 3
Redwood City 3
Shanghai 3
Battipaglia 2
Hebei 2
Hefei 2
Los Angeles 2
Napoli 2
Palermo 2
Rome 2
Sant'angelo Romano 2
Trieste 2
Anzio 1
Auburn Hills 1
Avigliano 1
Berlin 1
Caserta 1
Chengdu 1
Crotone 1
Easton 1
Fairfield 1
Fuzhou 1
Gurgaon 1
Huzhou 1
Lima 1
Manila 1
Nanchang 1
Nantong 1
Puyang Chengguanzhen 1
Saint Petersburg 1
San Mateo 1
Trento 1
Wuhan 1
Xian 1
Zhengzhou 1
Zhongxin 1
Totale 1.673
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 158
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 149
Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. 118
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus 113
Cytokine network and acute primary HIV-1 infection. 106
Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient 97
FARMACOCINETICA DEI FARMACI ANTIRETROVIRALI NELLA PRATICA CLINICA 96
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. 95
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters 86
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) 81
Oral lesions in children born to HIV-1 positive women. 77
Polyamines in lymphocytes from patients infected by human immunodeficiency virus. 75
Longitudinal analysis of the 90K glycoprotein in the Italian HIV-seroconversion study: temporal trend and predictability of the maturity of HIV infection. 75
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon 75
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon 73
Clinical pharmacology of antiretroviral therapy 72
Immunoglobulin and Myc gene structure in lymphnode biopsies from HIV-positive patients with LAS and lymphoma. 71
Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses. 69
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. 67
EFFETTO DI LOPINAVIR/RITONAVIR SULLE CONCENTRAZIONI PLASMATICHE DI TRIGLICERIDI E COLESTEROLO: VALUTAZIONE FARMACOCINETICA 66
Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. 64
An outbreak of HIV-1 subtype G among Italian injecting drug users. 64
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide 63
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. 62
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting 61
Lopinavir protein binding in vivo through the 12-hour dosing interval 61
Penetration of didanosine in semen of HIV-1-infected men 56
Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens 54
UTILITA' DEL THERAPEUTIC DRUG MONITORING DI NEVIRAPINA 51
Successful simplification of HAART in patients with acute primary HIV infection. 49
Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine 48
Treating advanced HIV infection. 47
Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. 45
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. 44
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. 43
The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy 42
Pharmacokinetics of saquinavir co-administered with cimetidine. 40
The relationship between nevirapine plasma concentrations and abnormal liver function tests 40
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. 35
Totale 2.788
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.810
article - articoli 0
book - libri 0
conference - conferenze 1.881
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.691
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020237 0 0 0 0 0 60 55 9 37 26 33 17
2020/2021267 42 1 40 12 16 11 23 2 48 33 10 29
2021/2022329 13 16 18 19 15 10 29 21 12 10 75 91
2022/2023462 53 10 7 42 54 132 39 28 65 4 16 12
2023/2024171 40 36 6 6 8 27 0 11 0 0 11 26
2024/2025349 0 11 7 40 236 55 0 0 0 0 0 0
Totale 2.788